Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma
https://iovs.arvojournals.org/article.aspx?articleid=2768349
Results : We found a significant correlation between midkine expression in primary uveal melanoma and overall survival. Patients with high midkine expression displayed only a 20% 5-year survival, whereas patients with low midkine levels displayed a 90% survival rate. (...)
Conclusions : Midkine is identified as a tumor cell survival factor that drives metastasis and therapeutic resistance, and could be exploited as a biomarker as well as therapeutic target in uveal melanoma.
- Forums
- ASX - By Stock
- AN1
- Midkine News 2020
Midkine News 2020, page-11
-
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $3.691M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $1.92K | 240K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 493225 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 615000 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 493225 | 0.007 |
2 | 516527 | 0.006 |
3 | 1000000 | 0.005 |
3 | 1075000 | 0.004 |
2 | 766667 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 615000 | 4 |
0.013 | 750000 | 1 |
0.015 | 340000 | 2 |
0.016 | 750000 | 2 |
0.017 | 150000 | 1 |
Last trade - 10.07am 21/06/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online